PDCD1 and inflammatory breast carcinoma: According to a recent Phase 2 trial, single-agent treatment with anti-programmed cell death 1 (PD-1) antibody pembrolizumab as maintenance therapy for metastatic IBC has reported a disease control rate of 47% after 5 months (Gao et al., 2020).